Altered control of the differentiated state of the smooth muscle cell (SMC) or "phenotypic switching" is known to play a critical role in the development and/or progression of a number of major human diseases including atherosclerosis, asthma, and post-angioplasty restenosis. However, the mechanisms that control SMC phenotypic switching are poorly understood. The focus of this proposal is to determine mechanisms by which histone patterning of chromatin, a key epigenetic control in higher eukaryotic cells, regulates SMC differentiation in development and disease. Of major significance, during the current funding period, we completed a series of pioneering studies showing that development of SMC from embryonic stem cells (ESC) is associated with acquisition of a unique pattern of histone modifications at SMC marker gene loci that distinguish them from non-SMC, and make these loci permissive for transcriptional activation. In contrast, phenotypic switching of SMC in response to vascular injury, or PDGF BB treatment, was associated with loss of many of these SMC-selective histone modifications, as well as acquisition of histone changes associated with transcriptional silencing/chromatin condensation. However, H3K4 demethylation at SMC marker gene loci, a histone change that appears during development of SMC from ESC, was completely unchanged in all models of SMC phenotypic switching examined, suggesting that it may be relatively "fixed", and serve to preserve SMC "lineage memory" during reversible phenotypic switching. Taken together, results indicate that there is a distinct pattern of histone modifications that distinguishes SMC from non-SMC, and that these SMC- and gene locus-specific epigenetic modifications are likely to play a key role in regulating SMC differentiation marker gene expression in development and disease. The focus of this project is to test the hypothesis that development of SMC from embryonic stem cells is associated with acquisition of a unique pattern of histone modifications at SMC marker (and regulatory) gene loci and that these histone modifications play a key role in determining the permissiveness of these gene loci for transcriptional activation as well as in providing "SMC lineage memory" during reversible phenotypic switching. We will address this hypothesis by addressing the following two specific aims.
Aim 1 is to determine mechanisms by which SMC selective/specific chromatin modifications regulate expression of SMC differentiation marker and regulatory genes during development of SMC lineages from multipotential stem cells. This will include the first studies to directly test the role of specific histone modifications in control of SMC lineage/differentiation, and how these histone modifications are acquired during development.
Aim 2 is to define the role of epigenetic modifications in mediating reversible phenotypic switching of vascular SMC in response to vascular injury in vivo or treatment of cultured SMC with PDGF BB. Studies will define fundamental mechanisms that control differentiation of SMC, and are likely to lead to novel therapies for treatment of diseases in which SMC phenotypic switching plays a major role.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL057353-15
Application #
8241146
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Srinivas, Pothur R
Project Start
1998-04-01
Project End
2013-05-31
Budget Start
2012-04-01
Budget End
2013-05-31
Support Year
15
Fiscal Year
2012
Total Cost
$373,794
Indirect Cost
$126,294
Name
University of Virginia
Department
Physiology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Shankman, Laura S; Gomez, Delphine; Cherepanova, Olga A et al. (2016) Corrigendum: KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 22:217
Gomez, Delphine; Owens, Gary K (2016) Reconciling Smooth Muscle Cell Oligoclonality and Proliferative Capacity in Experimental Atherosclerosis. Circ Res 119:1262-1264
Cherepanova, Olga A; Gomez, Delphine; Shankman, Laura S et al. (2016) Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective. Nat Med 22:657-65
Bennett, Martin R; Sinha, Sanjay; Owens, Gary K (2016) Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res 118:692-702
Cuttano, Roberto; Rudini, Noemi; Bravi, Luca et al. (2016) KLF4 is a key determinant in the development and progression of cerebral cavernous malformations. EMBO Mol Med 8:6-24
Wu, Jing; Montaniel, Kim Ramil C; Saleh, Mohamed A et al. (2016) Origin of Matrix-Producing Cells That Contribute to Aortic Fibrosis in Hypertension. Hypertension 67:461-8
Shankman, Laura S; Gomez, Delphine; Cherepanova, Olga A et al. (2015) KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 21:628-37
Tabas, Ira; García-Cardeña, Guillermo; Owens, Gary K (2015) Recent insights into the cellular biology of atherosclerosis. J Cell Biol 209:13-22
Nurnberg, S T; Cheng, K; Raiesdana, A et al. (2015) Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells that Contribute to the Fibrous Cap. Genom Data 5:36-37
Gomez, Delphine; Swiatlowska, Pamela; Owens, Gary K (2015) Epigenetic Control of Smooth Muscle Cell Identity and Lineage Memory. Arterioscler Thromb Vasc Biol 35:2508-16

Showing the most recent 10 out of 42 publications